Dr Charalampia Kyriakou

  • Qualifications
    MD, PhD
  • NHS Base
    Royal Free London NHS Foundation Trust and The North West London Hospitals NHS Trust (Northwick Park Hospital)
  • Speciality
  • Sub speciality
    Anaemias, multiple myeloma, paraproteinemias, lymphoma, myeloproliferative disorders (thrombocythaemia, polycythaemia), leukemia
  • Year qualified
  • Consulting address
    HCA Healthcare UK at University College Hospital, 5th Floor, Macmillan Cancer Centre, Huntley Street, London WC1E 6AG
  • Research interests
    Multiple myeloma, lymphoma, transplantation in myeloma and lymphoma, multiple myeloma spinal disease, quality of life in haematological malignancies
  • Languages
    English, Greek
  • Biography

    Dr Kyriakou obtained her medical degree at the Aristotelion University Thessaloniki, Greece. She had training in haematology at the transplant centre of George Papanikolaou Hospital and gained the title of Specialist in Haematology in 1996.

    She moved to London in 1997 and had further training at UCLH rotation. Dr Kyriakou was the transplant and multiple myeloma clinical research fellow at UCLH and she completed her PhD at University College London.

    Her main clinical interests are anaemias, lymphoma, plasma cell dyscrasias, multiple myeloma, myeloproliferative disorders (thrombocythaemia, polycythaemia), leukaemia and myeloma spinal and bone disease. She is actively involved on national and international clinical trials in haematological diseases.

    Dr Kyriakou is an active member of the:

    • Lymphoma working party of the European Group for Blood and Marrow Transplantation (EBMT)
    • International and UK Waldenstrom’s Macroglobulinemia group
    • EORTC Quality of Life group for haematological malignancies

    She is the lymphoma and multiple myeloma lead for the North West London NHS Trust: Northwick Park, St Mark’s and Central Middlesex Hospitals and a member of the American Society of Hematology and American Society of Clinical Oncology.

    Dr Kyriakou also performs autologous stem cell transplants for the treatment of multiple sclerosis.